Skip to main content
In stock | Immunotherapy (Checkpoint Inhibitor)

Sugemalimab

Oncology Type Solid Tumour
Drug Class / Mechanism Anti-PD-L1 Monoclonal Antibody
No Image
Description

Sugemalimab is classified as an Anti-PD-L1 Monoclonal Antibody, sourced for use within our Immunotherapy (Checkpoint Inhibitor) portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic Category Immunotherapy (Checkpoint Inhibitor)
Oncology Type Solid Tumour

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3